共 6 条
[1]
[2]
[3]
O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599.[J].A.B. Sandler;R. Gray;J. Brahmer;A. Dowlati;J.H. Schiller;M.C. Perry;D.H. Johnson.Lung Cancer.2005,
[4]
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with pathologic response.[J].Mitchell Machtay;Jason H Lee;James P Stevenson;Joseph B Shrager;Kenneth M Algazy;Joseph Treat;Larry R Kaiser.The Journal of Thoracic and Cardiovascular Surgery.2004, 1
[5]
Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non–small-cell lung cancer: a meta-analysis.[J].Eileen Rakovitch;May Tsao;Yee Ung;Jean-Philippe Pignol;Patrick Cheung;Edward Chow.International Journal of Radiation Oncology; Biology; Physics.2004, 1

